Saturday, November 23, 2024
11/23/2024
ABSTRACT Support is requested for a Keystone Symposia conference entitled NASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics, organized by Drs. Stefano Romeo, Michael Charlton, Silvia Sookoian and Gregory Tesz. The conference will be held in Banff, Canada from March 3-6, 2024. Fatty liver disease (FLD) includes a spectrum of conditions in which excess liver fat coexists with inflammation, fibrosis and increased risk of cancer. The incidence and prevalence of FLD is increasing rapidly and affects about one out of four people across the globe, with concurrent increases in liver related morbidity and mortality. Moreover, despite over a decade of research, clinical trials have failed to bring effective treatments for FLD with fibrosis. The complex and variable interactions between environmental and genetic susceptibility and protective factors have presented challenges to progress. Assessing severity of disease and response to therapy have been similarly challenging. Therefore, this Keystone Symposia conference program will explore the metabolic, genetic and molecular diversity of FLD to identify novel strategies to tackle this disease. The program will examine the latest advances in noninvasive measurements to both assess treatment efficacy as well as identify subpopulations at risk for liver-related events and mortality. Sessions will explore novel drug targets deriving from human genetics studies of variants protective against FLD. Ultimately, these advances will pave the way to precision therapeutics to treat NASH, fibrosis and cancer.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
